Celltrion announced on Wednesday that it plans to repurchase 537,924 shares, valued at around 100 billion won ($72 million), starting next Monday through an open-market buyback.

This marks Celltrion’s fourth share buyback this year, following earlier purchases in March, April, and June totaling over 75 billion won each. With the latest buyback, Celltrion will have acquired approximately 1.81 million shares this year, amounting to about 334.6 billion won.

Celltrion has consistently engaged in shareholder value enhancement initiatives, buying back shares worth approximately 1.26 trillion won last year. In addition to repurchasing shares, Celltrion has retired a significant portion to boost shareholder value—earlier this year, it retired approximately 2.3 million shares (496 billion won) in January and 1.12 million shares (200 billion won) in April, amounting to nearly 700 billion won.

Buybacks and share retirement are notable shareholder value enhancement strategies. By reducing the volume of shares available on the market, these actions can elevate the value of shares held by existing shareholders.

Celltrion’s decision aligns with its assessment that its corporate value is currently undervalued, despite expanding market share for its key products globally, launching new treatments, and advancing clinical trials for its pipeline.

One of Celltrion’s latest drugs, Zymfentra, has rapidly gained U.S. market access, securing coverage with Express Scripts and other leading pharmacy benefit managers (PBMs), now listed by over 80 percent of PBMs nationwide. Celltrion has also successfully obtained regulatory approvals for new biosimilars, including Omlyclo, Eydenzelt, and Steqeyma, which have bolstered its portfolio to nine biosimilars.

Celltrion is separately advancing approvals for follow-up biosimilars, such as for rheumatoid arthritis treatment Actemra, osteoporosis treatment Prolia, and multiple sclerosis therapy Ocrevus.

“In a robust phase of global market expansion for our core products and the steady release of new drugs, Celltrion decided on the additional buyback to enhance shareholder value,” a company official said. “Moving forward, Celltrion will continue to strengthen shareholder value through stock buybacks, share retirement, and consistent dividend policies.”